Amneal Pharmaceuticals (AMRX) Proxy filing summary

Executive summary

• Entered into a definitive agreement to acquire 100% of Kashiv BioSciences, a vertically integrated biopharmaceutical company, pending shareholder and regulatory approvals.

• Acquisition aims to position the company as a global biosimilars leader and expand access to affordable biologic medicines.

• Preliminary Q1 2026 results show strong performance: $723M net revenue (+4%), $80M income before tax (+114%), $202M adjusted EBITDA (+19%) compared to Q1 2025.

• Forward-looking statements highlight expectations for long-term growth and leadership in affordable medicines, subject to various risks and uncertainties.

Voting matters and shareholder proposals

• Shareholder approval is required for the proposed acquisition of Kashiv BioSciences.

• Proxy materials and related documents will be filed with the SEC and distributed to shareholders for voting.

Board of directors and corporate governance

• Directors and certain executive officers may participate in the proxy solicitation for the acquisition.

• Information about directors, executive officers, and their security holdings is available in the 2026 annual meeting proxy statement.